There are 449 resources available
102TiP - A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mut
Presenter: Yi-Long Wu
Session: Poster Display session
103TiP - Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)
Presenter: Fabrice Barlesi
Session: Poster Display session
105TiP - Adebrelimab combined with famitinib in the treatment of PD-L1≥50% advanced non-small cell lung cancer with brain metastases: A prospective, single-arm trial (BRAIN-AF01)
Presenter: Weiran Xu
Session: Poster Display session
107TiP - Dry powder inhaled cisplatin in stage IV NSCLC: The phase I/IIa CIS-DPI-01 study
Presenter: Mariana Brandão
Session: Poster Display session
109P - A revised international association for the study of lung cancer grading system in invasive pulmonary adenocarcinoma: The inclusion of invasive mucinous adenocarcinomas
Presenter: Hanyue Li
Session: Poster Display session
110P - The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma
Presenter: Chia Liu
Session: Poster Display session
112P - Treatment landscape for stages I–III NSCLC in the United States (US) community setting before and after 2020
Presenter: Jessica Donington
Session: Poster Display session
113P - A propensity-based analysis of SBRT and VATS for early-stage lung cancer: A guide to data-driven support and decision-making in a multidisciplinary tumour board
Presenter: Olivier Van kerkhove
Session: Poster Display session
114P - Efficacy of perioperative/neoadjuvant immunotherapy combined with chemotherapy: Pooled analysis of specific subgroups in randomized controlled trials
Presenter: yakup ergün
Session: Poster Display session